Randomized, Double-Blind, Placebo-Controlled Trial of Erythropoietin in Non–Small-Cell Lung Cancer With Disease-Related Anemia
Top Cited Papers
- 20 March 2007
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (9) , 1027-1032
- https://doi.org/10.1200/jco.2006.07.1514
Abstract
Purpose Previous trials have suggested a quality-of-life (QOL) improvement for anemic cancer patients treated with erythropoietin, but few used QOL as the primary outcome. We designed a trial to investigate the effects of epoetin alfa therapy on the QOL of anemic patients with advanced non–small-cell carcinoma of the lung (NSCLC). Patients and Methods A multicenter, randomized, double-blind, placebo-controlled trial was conducted. The proposed sample size was 300 patients. Eligible patients were required to have NSCLC unsuitable for curative therapy and baseline hemoglobin (Hgb) levels less than 121 g/L. Patients were assigned to 12 weekly injections of subcutaneous epoetin alpha or placebo, targeting Hgb levels between 120 and 140 g/L. The primary outcome was the difference in the change in Functional Assessment of Cancer Therapy–Anemia scores between baseline and 12 weeks. Results Reports of thrombotic events in other epoetin trials prompted an unplanned safety analysis after 70 patients had been randomly assigned (33 to the active arm and 37 to the placebo arm). This revealed a significant difference in the median survival in favor of the patients on the placebo arm of the trial (63 v 129 days; hazard ratio, 1.84; P = .04). The Steering Committee closed the trial. Patient numbers compromised the interpretation of the QOL analysis, but a positive Hgb response was noted with epoetin alfa treatment. Conclusion An unplanned safety analysis suggested decreased overall survival in patients with advanced NSCLC treated with epoetin alfa. Although infrequent, other similar reports highlight the need for ongoing trials evaluating erythropoietin receptor agonists to ensure that overall survival is monitored closely.Keywords
This publication has 26 references indexed in Scilit:
- Efficacy and Safety Analysis of Epoetin Alfa in Patients With Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled TrialJournal of Clinical Oncology, 2005
- Erythropoietin Use in Cancer Patients: A Matter of Life and Death?Journal of Clinical Oncology, 2005
- Standards of Proof, Standards of Practice, and Proof of Standards: A Tale of Two TrialsJournal of Clinical Oncology, 2005
- EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancerEuropean Journal Of Cancer, 2004
- Ipsilateral breast tumor recurrence (IBTR) following breast conservation therapy: Outcomes of salvage mastectomy (SM) vs. salvage breast conserving surgery (SBCS) and prognostic factors for salvage breast preservationInternational Journal of Radiation Oncology*Biology*Physics, 2004
- Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trialThe Lancet, 2003
- Fatigue in cancer patients compared with fatigue in the general United States populationCancer, 2002
- Proportional hazards tests and diagnostics based on weighted residualsBiometrika, 1994
- Partial residuals for the proportional hazards regression modelBiometrika, 1982
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958